ACS Pharmacology & Translational Science

, volume 4 , issue 2 , pages 573-577

Ethical Concerns about Psilocybin Intellectual Property

Konstantin Gerber ¹

Inti García Flores ²

Angela Christina Ruiz ³

Ismail Ali ⁴

Natalie Lyla Ginsberg ⁴

Eduardo Ekman Schenberg ⁵

Hide authors affiliations Show authors affiliations: 5 affiliations

Pontifical Catholic University of São Paulo, São Paulo, 05014-901, Brazil |

Archivo “Historias y Memorias Mazatecas”, Huautla de Jiménez, 68500, Mexico |

Letterevolution.com, Luzern, 6006, Switzerland |

⁴

Multidisciplinary Association for Psychedelic Studies, Santa Cruz, California 95060-9989, United States |

⁵

Instituto Phaneros, São Paulo, 01451-001, Brazil |

Publication type: Journal Article

Publication date: 2021-01-01

American Chemical Society (ACS)

ACS Pharmacology & Translational Science

scimago Q1

wos Q2

SJR: 1.230

CiteScore: 7.5

Impact factor: 3.7

ISSN: 25759108

DOI: 10.1021/acsptsci.0c00171

Copy DOI

PubMed ID: 33860186

Pharmacology

Pharmacology (medical)

Abstract

Since a 1957 exposé in Life Magazine, chemical compounds derived from Psilocybe mushrooms have been the focus of dozens of attempted and successful patents, most recently to treat depression. Regrettably, the Mazatec indigenous communities who stewarded these traditional medicines for millenia are not party to any of these patents, despite a number of international treaties asserting indigenous rights to their intangible cultural heritage.

Found

1 citation

Buchman Daniel

93 publications, 1 295 citations, 6 reviews

h-index: 19

University of Toronto

Centre for Addiction and Mental Health

Top-30

Journals

	1 2 3 4
Journal of Psychedelic Studies	Journal of Psychedelic Studies, 4, 10% Journal of Psychedelic Studies 4 publications, 10%
Anthropology of Consciousness	Anthropology of Consciousness, 3, 7.5% Anthropology of Consciousness 3 publications, 7.5%
Transcultural Psychiatry	Transcultural Psychiatry, 2, 5% Transcultural Psychiatry 2 publications, 5%
Frontiers in Pharmacology	Frontiers in Pharmacology, 2, 5% Frontiers in Pharmacology 2 publications, 5%
Frontiers in Psychology	Frontiers in Psychology, 2, 5% Frontiers in Psychology 2 publications, 5%
Interdisciplinary Science Reviews	Interdisciplinary Science Reviews, 2, 5% Interdisciplinary Science Reviews 2 publications, 5%
Frontiers in Psychiatry	Frontiers in Psychiatry, 1, 2.5% Frontiers in Psychiatry 1 publication, 2.5%
3 Biotech	3 Biotech, 1, 2.5% 3 Biotech 1 publication, 2.5%
Journal of Ethnopharmacology	Journal of Ethnopharmacology, 1, 2.5% Journal of Ethnopharmacology 1 publication, 2.5%
Fungal Biology	Fungal Biology, 1, 2.5% Fungal Biology 1 publication, 2.5%
Neuropharmacology	Neuropharmacology, 1, 2.5% Neuropharmacology 1 publication, 2.5%
ACS Pharmacology & Translational Science	ACS Pharmacology & Translational Science, 1, 2.5% ACS Pharmacology & Translational Science 1 publication, 2.5%
Heliyon	Heliyon, 1, 2.5% Heliyon 1 publication, 2.5%
Drogues santé et société	Drogues santé et société, 1, 2.5% Drogues santé et société 1 publication, 2.5%
Philosophies	Philosophies, 1, 2.5% Philosophies 1 publication, 2.5%
Drugs: Education, Prevention and Policy	Drugs: Education, Prevention and Policy, 1, 2.5% Drugs: Education, Prevention and Policy 1 publication, 2.5%
Deleuze and Guattari Studies	Deleuze and Guattari Studies, 1, 2.5% Deleuze and Guattari Studies 1 publication, 2.5%
Journal of Military Veteran and Family Health	Journal of Military Veteran and Family Health, 1, 2.5% Journal of Military Veteran and Family Health 1 publication, 2.5%
American Journal of Psychiatry	American Journal of Psychiatry, 1, 2.5% American Journal of Psychiatry 1 publication, 2.5%
International Journal of Mental Health and Addiction	International Journal of Mental Health and Addiction, 1, 2.5% International Journal of Mental Health and Addiction 1 publication, 2.5%
Public Health Ethics	Public Health Ethics, 1, 2.5% Public Health Ethics 1 publication, 2.5%
JAMA network open	JAMA network open, 1, 2.5% JAMA network open 1 publication, 2.5%
Health Education and Behavior	Health Education and Behavior, 1, 2.5% Health Education and Behavior 1 publication, 2.5%
Nature Chemistry	Nature Chemistry, 1, 2.5% Nature Chemistry 1 publication, 2.5%
Handbook of Research on Teaching Methods in Language Translation and Interpretation	Handbook of Research on Teaching Methods in Language Translation and Interpretation, 1, 2.5% Handbook of Research on Teaching Methods in Language Translation and Interpretation 1 publication, 2.5%
PLOS Global Public Health	PLOS Global Public Health, 1, 2.5% PLOS Global Public Health 1 publication, 2.5%
Trends in Biotechnology	Trends in Biotechnology, 1, 2.5% Trends in Biotechnology 1 publication, 2.5%
Developments in Neuroethics and Bioethics	Developments in Neuroethics and Bioethics, 1, 2.5% Developments in Neuroethics and Bioethics 1 publication, 2.5%
Contemporary Drug Problems	Contemporary Drug Problems, 1, 2.5% Contemporary Drug Problems 1 publication, 2.5%
	1 2 3 4

Publishers

	1 2 3 4 5 6
SAGE	SAGE, 6, 15% SAGE 6 publications, 15%
Elsevier	Elsevier, 6, 15% Elsevier 6 publications, 15%
Frontiers Media S.A.	Frontiers Media S.A., 5, 12.5% Frontiers Media S.A. 5 publications, 12.5%
Springer Nature	Springer Nature, 5, 12.5% Springer Nature 5 publications, 12.5%
Akademiai Kiado	Akademiai Kiado, 4, 10% Akademiai Kiado 4 publications, 10%
Wiley	Wiley, 3, 7.5% Wiley 3 publications, 7.5%
American Chemical Society (ACS)	American Chemical Society (ACS), 1, 2.5% American Chemical Society (ACS) 1 publication, 2.5%
Consortium Erudit	Consortium Erudit, 1, 2.5% Consortium Erudit 1 publication, 2.5%
MDPI	MDPI, 1, 2.5% MDPI 1 publication, 2.5%
Taylor & Francis	Taylor & Francis, 1, 2.5% Taylor & Francis 1 publication, 2.5%
Edinburgh University Press	Edinburgh University Press, 1, 2.5% Edinburgh University Press 1 publication, 2.5%
University of Toronto Press Inc. (UTPress)	University of Toronto Press Inc. (UTPress), 1, 2.5% University of Toronto Press Inc. (UTPress) 1 publication, 2.5%
American Psychiatric Association Publishing	American Psychiatric Association Publishing, 1, 2.5% American Psychiatric Association Publishing 1 publication, 2.5%
Oxford University Press	Oxford University Press, 1, 2.5% Oxford University Press 1 publication, 2.5%
American Medical Association (AMA)	American Medical Association (AMA), 1, 2.5% American Medical Association (AMA) 1 publication, 2.5%
IGI Global	IGI Global, 1, 2.5% IGI Global 1 publication, 2.5%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 2.5% Public Library of Science (PLoS) 1 publication, 2.5%
	1 2 3 4 5 6

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Gerber K. et al. Ethical Concerns about Psilocybin Intellectual Property // ACS Pharmacology & Translational Science. 2021. Vol. 4. No. 2. pp. 573-577.

GOST all authors (up to 50) Copy

Gerber K., Flores I. G., Ruiz A. C., Ali I., Ginsberg N. L., Schenberg E. E. Ethical Concerns about Psilocybin Intellectual Property // ACS Pharmacology & Translational Science. 2021. Vol. 4. No. 2. pp. 573-577.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1021/acsptsci.0c00171

UR - https://doi.org/10.1021/acsptsci.0c00171

TI - Ethical Concerns about Psilocybin Intellectual Property

T2 - ACS Pharmacology & Translational Science

AU - Gerber, Konstantin

AU - Flores, Inti García

AU - Ruiz, Angela Christina

AU - Ali, Ismail

AU - Ginsberg, Natalie Lyla

AU - Schenberg, Eduardo Ekman

PY - 2021

DA - 2021/01/01

PB - American Chemical Society (ACS)

SP - 573-577

IS - 2

VL - 4

PMID - 33860186

SN - 2575-9108

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2021_Gerber,

author = {Konstantin Gerber and Inti García Flores and Angela Christina Ruiz and Ismail Ali and Natalie Lyla Ginsberg and Eduardo Ekman Schenberg},

title = {Ethical Concerns about Psilocybin Intellectual Property},

journal = {ACS Pharmacology & Translational Science},

year = {2021},

volume = {4},

publisher = {American Chemical Society (ACS)},

month = {jan},

url = {https://doi.org/10.1021/acsptsci.0c00171},

number = {2},

pages = {573--577},

doi = {10.1021/acsptsci.0c00171}

}

MLA

Cite this

MLA Copy

Gerber, Konstantin, et al. “Ethical Concerns about Psilocybin Intellectual Property.” ACS Pharmacology & Translational Science, vol. 4, no. 2, Jan. 2021, pp. 573-577. https://doi.org/10.1021/acsptsci.0c00171.

Publisher

American Chemical Society (ACS)

Journal

ACS Pharmacology & Translational Science

scimago Q1

wos Q2

SJR

1.230

CiteScore

7.5

Impact factor

3.7

ISSN

25759108 (Print, Electronic)